The aims of this retrospective-prospective study were to investigate the presumed etiology and the risk of stroke following clustering transient ischemic attacks (TIAs). Among all patients with TIAs examined in a 5-year period, 70 had multiple (>2) TIAs recurring at intervals of less than 24 h. TIAs were either in the carotid (repetitive hemiplegia in 46 subjects, amaurosis fugax in 6 and aphasia in 7) or the vertebrobasilar (11 patients) territory. A potential cardiac source of embolism was disclosed in 7 (10%) patients. Extracranial vessel disease was considered the most plausible etiology of the TIAs in 12 patients. Intracranial vascular abnormalities were found in 5 subjects. Twenty-seven patients presented with TIAs which were brief expressions of classic lacunar syndromes. Fourteen had an appropriate lacunar infarct on CT. Patients with amaurosis fugax had the highest prevalence of extracranial vessel disease. Twenty-one patients suffered an ischemic stroke within 48 h of the last TIA, despite 5 being on heparin. The highest rate of stroke (32%) was found among patients with repetitive attacks of hemiplegia. On follow-up (mean 13.1 months) 18 subjects had recurrent TIAs but only 2 suffered a stroke. In conclusion, in the majority of cases, clustering TIAs are related to smaIl-vessel disease and carry a high risk of immediate stroke. Clustering TIAs are one of the clinical presentations of single-perforator-vessel-territory ischemia.

Keywords:
TIA, Clustering TIA, Stroke prognosis, Lacunar stroke, Anticoagulants, Small vessel disease
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.